HEAL DSpace

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Dahabreh, IJ en
dc.contributor.author Zoi, K en
dc.contributor.author Giannouli, S en
dc.contributor.author Zoi, C en
dc.contributor.author Loukopoulos, D en
dc.contributor.author Voulgarelis, M en
dc.date.accessioned 2014-03-01T01:58:54Z
dc.date.available 2014-03-01T01:58:54Z
dc.date.issued 2009 en
dc.identifier.issn 0145-2126 en
dc.identifier.uri http://hdl.handle.net/123456789/28779
dc.subject Essential thrombocythemia en
dc.subject JAK2 V617F en
dc.subject Thrombosis en
dc.subject Systematic review en
dc.subject Meta-analysis en
dc.subject.classification Oncology en
dc.subject.classification Hematology en
dc.subject.other CHRONIC MYELOPROLIFERATIVE DISORDERS en
dc.subject.other POLYCYTHEMIA-VERA en
dc.subject.other JAK2(V617F) MUTATION en
dc.subject.other ALLELE BURDEN en
dc.subject.other RISK-FACTORS en
dc.subject.other 617V-GREATER-THAN-F MUTATION en
dc.subject.other LEUKOCYTE ACTIVATION en
dc.subject.other JAK2-V617F MUTATION en
dc.subject.other THROMBOSIS en
dc.subject.other MYELOFIBROSIS en
dc.title Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia en
heal.type journalArticle en
heal.language English en
heal.publicationDate 2009 en
heal.abstract A systematic review and meta-analysis was carried out to compare the frequency of clinically significant outcomes between JAK2 V617F positive and wild type patients with essential thrombocythemia (ET). JAK2 V617F positivity in patients with ET was associated with a clear increase in the odds of thrombosis [OR = 1.83 (95% CI, 1.32-2.53), p < 0.0001], and much higher odds of transformation to polycythemia vera [OR = 7.67 (95% Cl, 2.04-28.87), p = 0.0009]. The mean difference of the white blood cell count between JAK2 positive and negative patients was associated with an increased odds ratio for thrombosis (p = 0.02). The JAK2 V617F mutation in patients with ET is associated with an increased risk of adverse cardiovascular outcomes via an increase in the leukocyte count. (C) 2008 Elsevier Ltd. All rights reserved. en
heal.publisher PERGAMON-ELSEVIER SCIENCE LTD en
heal.journalName LEUKEMIA RESEARCH en
dc.identifier.isi ISI:000261680400010 en
dc.identifier.volume 33 en
dc.identifier.issue 1 en
dc.identifier.spage 67 en
dc.identifier.epage 73 en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record